In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The ...

Investment analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Perspective ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...

Discover Celcuity's Q4 2024 insights: gedatolisib's promising trials for breast cancer, $2B market potential, and key 2025 milestones.

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on InflaRx (IFRX – Research Report). The company’s shares ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. Analyst Price Forecast Suggests 145.23% Upside As ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares clo ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. As of March 4, 2025, the average one-year ...

Insiders have been showing their love for these four biotech stocks, and one tech stock, lately with huge share purchases.